KDM7

KDM7 (lysine demethylase 7), particularly KDM7A/KIAA1718, is a JmjC-domain histone demethylase that removes transcriptionally repressive histone methylation marks and thereby regulates chromatin accessibility and gene expression programs^[1][2]. Mechanistically, KDM7A displays dual specificity toward H3K9me2 and H3K27me2, two epigenetic marks associated with transcriptional repression, linking KDM7 activity directly to developmental gene regulation and cell fate determination^[1][2]. During neural differentiation, KDM7A regulates developmental transcriptional programs through modulation of the FGF4 pathway, demonstrating a key role in lineage specification and neurodevelopmental processes^[2]. Consistent with these functions, KDM7 family members have been implicated in development, transcriptional regulation, and multiple disease contexts, including cancer, where aberrant epigenetic control contributes to altered cellular proliferation and differentiation programs^[3]. Compared with related KDM7 family isoforms, KDM7A is distinguished by its well-characterized dual demethylase activity toward both H3K9 and H3K27 methylation states, whereas other family members exhibit distinct substrate preferences and regulatory properties that influence their biological functions^[1][3]. For experimental applications, pharmacological inhibition of the KDM2/7 subfamily has been achieved using small-molecule inhibitors such as NCDM-32B/NCDM-64, which were developed as selective KDM2/7 inhibitors and showed antiproliferative activity in cancer cell models, providing useful chemical tools for epigenetic and disease-related research^[4].

References: